ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jan 26, 2023 13:16 JST
Source:
Prenetics Global Limited
Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating
Target Price at USD7.00
HONG KONG, Jan 26, 2023 - (ACN Newswire) - It is reported that Cantor Fitzgerald initiated coverage on Prenetics Global (PRE.US) with "Overweight" rating and target price at USD7.00.
Cantor Fitzgerald holds a favorable view of the consumer and clinical testing markets, with Prenetics' focus on diagnostic and preventive testing coupled with personalized and primary care facilities to address a global market opportunity of over $200 billion. In addition, Cantor Fitzgerald believes its commercialization strategy in rolling out tests both via B2C and B2B in the future, depending on which avenue will result in the broadest adoption with the lowest amount of operating expenses, is unique and sound. Prenetics looks to add new tests to its platform through acquisitions and partnerships, resulting in faster time to market and a comprehensive healthcare ecosystem in a not-so-distant future.
Meanwhile, with Prenetics' ecosystem coming together and being able to uniquely demonstrate profitability given its lower operating expenses and R&D expenses relative to peers, Cantor Fitzgerald thinks Prenetics' shares are also attractively valued.
In the near term, Prenetics will focus on Hong Kong, Southeast Asia and the UK, where the company has strong leadership teams in place and benefits from little to no competition, most notably in Asia.
Source: Prenetics Global Limited
Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Hong Kong Watch & Clock Fair, Salon de TIME return in September
Aug 31, 2025 12:30 JST
Honda Announces New Plan for Relocation of Global Head Office to Yaesu Area in Tokyo and Reconstruction of Honda Aoyama Building
Aug 29, 2025 18:54 JST
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 29, 2025 18:17 JST
Hitachi Energy acquires remaining stake of eks Energy, reinforcing leadership in power conversion systems for energy storage
Aug 29, 2025 15:17 JST
SenseTime Announces 2025 Interim Results
Aug 28, 2025 21:20 JST
Ausnutria 2025 Interim Results Announcement: Revenue and Profit Maintain Resilient Dual Growth
Aug 28, 2025 19:09 JST
Baguio Green Group (1397.HK) Announces 2025 Interim Results
Aug 28, 2025 19:03 JST
Production, Sales and Export Results for July, 2025
Aug 28, 2025 17:36 JST
Sales, Production, and Export Results for July 2025
Aug 28, 2025 17:25 JST
The University of Tokyo and DENSO Jointly Establish a Social Cooperation Program: "Building Sustainable Production System Infrastructure with Advanced AI Technology"
Aug 28, 2025 16:33 JST
Overview of Honda Exhibits at the Japan Mobility Show 2025
Aug 28, 2025 15:49 JST
NEC develops AI technology for digitalizing work tasks without the need for pre-training and utilizing video from multiple cameras covering wide area worksites
Aug 27, 2025 22:57 JST
Result of the Business Plan Review for the Offshore Wind Power Generation Projects in Japan
Aug 27, 2025 22:27 JST
Fujitsu develops AI agent platform for the healthcare sector to enhance operational efficiency and ensure stable medical service provision
Aug 27, 2025 21:50 JST
MHI Becomes First Japanese Company to Acquire ISO 19443:2018 Certification in the Nuclear Energy Field
Aug 27, 2025 21:32 JST
Mitsubishi Logisnext to Demonstrate Automated Forklift Equipped with "SynfoX" at "4th INNOVATION EXPO"
Aug 27, 2025 20:59 JST
TANAKA to Showcase Advanced Semiconductor Materials in its Inaugural Participation at SEMICON India 2025
Aug 26, 2025 13:30 JST
Honda to Hold Official e-Motorsports Event, "Honda Racing eMS 2025"
Aug 26, 2025 13:17 JST
Mitsubishi Corporation Invests in Fullerton Health
Aug 26, 2025 12:54 JST
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 25, 2025 19:30 JST
More Latest Release >>
Related Release
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture "Insighta" for Breakthrough Multi-Cancer Early Detection Screening
June 26 2023 09:37 JST
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology
March 14 2023 22:05 JST
Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
March 04 2023 15:40 JST
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
January 11 2023 11:19 JST
Prenetics Acquires ACT Genomics; First M&A Deal since IPO, Set to Expand Footprint in Cancer Genomics
December 16 2022 19:57 JST
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
November 30 2022 22:43 JST
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
November 10 2022 21:36 JST
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
September 09 2022 21:54 JST
More Press release >>